Imipramine in the treatment of social phobia
We report the results of an 8-week open trial of imipramine in 15 patients with social phobia. Nine patients completed the trial; six dropped out early because of adverse effects. The mean reduction in the Liebowitz Social Anxiety Scale was 15% and 18% for the intent-to-treat and completer groups, r...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical psychopharmacology 1998-04, Vol.18 (2), p.132-135 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 135 |
|---|---|
| container_issue | 2 |
| container_start_page | 132 |
| container_title | Journal of clinical psychopharmacology |
| container_volume | 18 |
| creator | SIMPSON, H. B SCHNEIER, F. R CAMPEAS, R. B MARSHALL, R. D FALLON, B. A DAVIES, S KLEIN, D. F LIEBOWITZ, M. R |
| description | We report the results of an 8-week open trial of imipramine in 15 patients with social phobia. Nine patients completed the trial; six dropped out early because of adverse effects. The mean reduction in the Liebowitz Social Anxiety Scale was 15% and 18% for the intent-to-treat and completer groups, respectively; the overall response rate (based on the Clinical Global Impression Scale of 1 or 2, very much or much improved) was 20% (3/15) and 22% (2/9), respectively. The results from this open trial do not support the efficacy of imipramine as a treatment for social phobia. |
| doi_str_mv | 10.1097/00004714-199804000-00005 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00004714_199804000_00005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9555598</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-51ae536111eb2a056a08401a6d913dc75248d2266663dae9a7708da4922f164d3</originalsourceid><addsrcrecordid>eNo9j81LAzEQxYMotVb_BCEHj0Yz-dwcpVgtFLwoeFummyyNdD9I1oP_vVtb912GeW_ewI8QCvwBuLOPfJSyoBg4V3A1buxg6TMyBy0lsyA-z8mcCwuMW-UuyVXOX5yDskLPyMzpUa6Yk_t1E_uETWwDjS0ddoEOKeDQhHagXU1zV0Xc037XbSNek4sa9zncnOaCfKye35evbPP2sl4-bVglpRuYBgxaGgAIW4FcG-SF4oDGO5C-slqowgthRkmPwaG1vPConBA1GOXlghTHv1Xqck6hLvsUG0w_JfDywF_-85cT_5-lx-rtsdp_b5vgp-IJeMzvTjnmCvd1wraKeToTQoBxRv4ChP5gQw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Imipramine in the treatment of social phobia</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>SIMPSON, H. B ; SCHNEIER, F. R ; CAMPEAS, R. B ; MARSHALL, R. D ; FALLON, B. A ; DAVIES, S ; KLEIN, D. F ; LIEBOWITZ, M. R</creator><creatorcontrib>SIMPSON, H. B ; SCHNEIER, F. R ; CAMPEAS, R. B ; MARSHALL, R. D ; FALLON, B. A ; DAVIES, S ; KLEIN, D. F ; LIEBOWITZ, M. R</creatorcontrib><description>We report the results of an 8-week open trial of imipramine in 15 patients with social phobia. Nine patients completed the trial; six dropped out early because of adverse effects. The mean reduction in the Liebowitz Social Anxiety Scale was 15% and 18% for the intent-to-treat and completer groups, respectively; the overall response rate (based on the Clinical Global Impression Scale of 1 or 2, very much or much improved) was 20% (3/15) and 22% (2/9), respectively. The results from this open trial do not support the efficacy of imipramine as a treatment for social phobia.</description><identifier>ISSN: 0271-0749</identifier><identifier>EISSN: 1533-712X</identifier><identifier>DOI: 10.1097/00004714-199804000-00005</identifier><identifier>PMID: 9555598</identifier><identifier>CODEN: JCPYDR</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Antidepressive Agents, Tricyclic - adverse effects ; Antidepressive Agents, Tricyclic - therapeutic use ; Biological and medical sciences ; Female ; Humans ; Imipramine - adverse effects ; Imipramine - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Pharmacology. Drug treatments ; Phobic Disorders - drug therapy ; Phobic Disorders - psychology ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Single-Blind Method</subject><ispartof>Journal of clinical psychopharmacology, 1998-04, Vol.18 (2), p.132-135</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-51ae536111eb2a056a08401a6d913dc75248d2266663dae9a7708da4922f164d3</citedby><cites>FETCH-LOGICAL-c339t-51ae536111eb2a056a08401a6d913dc75248d2266663dae9a7708da4922f164d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2221696$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9555598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SIMPSON, H. B</creatorcontrib><creatorcontrib>SCHNEIER, F. R</creatorcontrib><creatorcontrib>CAMPEAS, R. B</creatorcontrib><creatorcontrib>MARSHALL, R. D</creatorcontrib><creatorcontrib>FALLON, B. A</creatorcontrib><creatorcontrib>DAVIES, S</creatorcontrib><creatorcontrib>KLEIN, D. F</creatorcontrib><creatorcontrib>LIEBOWITZ, M. R</creatorcontrib><title>Imipramine in the treatment of social phobia</title><title>Journal of clinical psychopharmacology</title><addtitle>J Clin Psychopharmacol</addtitle><description>We report the results of an 8-week open trial of imipramine in 15 patients with social phobia. Nine patients completed the trial; six dropped out early because of adverse effects. The mean reduction in the Liebowitz Social Anxiety Scale was 15% and 18% for the intent-to-treat and completer groups, respectively; the overall response rate (based on the Clinical Global Impression Scale of 1 or 2, very much or much improved) was 20% (3/15) and 22% (2/9), respectively. The results from this open trial do not support the efficacy of imipramine as a treatment for social phobia.</description><subject>Adult</subject><subject>Antidepressive Agents, Tricyclic - adverse effects</subject><subject>Antidepressive Agents, Tricyclic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Humans</subject><subject>Imipramine - adverse effects</subject><subject>Imipramine - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phobic Disorders - drug therapy</subject><subject>Phobic Disorders - psychology</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Single-Blind Method</subject><issn>0271-0749</issn><issn>1533-712X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j81LAzEQxYMotVb_BCEHj0Yz-dwcpVgtFLwoeFummyyNdD9I1oP_vVtb912GeW_ewI8QCvwBuLOPfJSyoBg4V3A1buxg6TMyBy0lsyA-z8mcCwuMW-UuyVXOX5yDskLPyMzpUa6Yk_t1E_uETWwDjS0ddoEOKeDQhHagXU1zV0Xc037XbSNek4sa9zncnOaCfKye35evbPP2sl4-bVglpRuYBgxaGgAIW4FcG-SF4oDGO5C-slqowgthRkmPwaG1vPConBA1GOXlghTHv1Xqck6hLvsUG0w_JfDywF_-85cT_5-lx-rtsdp_b5vgp-IJeMzvTjnmCvd1wraKeToTQoBxRv4ChP5gQw</recordid><startdate>19980401</startdate><enddate>19980401</enddate><creator>SIMPSON, H. B</creator><creator>SCHNEIER, F. R</creator><creator>CAMPEAS, R. B</creator><creator>MARSHALL, R. D</creator><creator>FALLON, B. A</creator><creator>DAVIES, S</creator><creator>KLEIN, D. F</creator><creator>LIEBOWITZ, M. R</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19980401</creationdate><title>Imipramine in the treatment of social phobia</title><author>SIMPSON, H. B ; SCHNEIER, F. R ; CAMPEAS, R. B ; MARSHALL, R. D ; FALLON, B. A ; DAVIES, S ; KLEIN, D. F ; LIEBOWITZ, M. R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-51ae536111eb2a056a08401a6d913dc75248d2266663dae9a7708da4922f164d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Antidepressive Agents, Tricyclic - adverse effects</topic><topic>Antidepressive Agents, Tricyclic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Humans</topic><topic>Imipramine - adverse effects</topic><topic>Imipramine - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phobic Disorders - drug therapy</topic><topic>Phobic Disorders - psychology</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Single-Blind Method</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SIMPSON, H. B</creatorcontrib><creatorcontrib>SCHNEIER, F. R</creatorcontrib><creatorcontrib>CAMPEAS, R. B</creatorcontrib><creatorcontrib>MARSHALL, R. D</creatorcontrib><creatorcontrib>FALLON, B. A</creatorcontrib><creatorcontrib>DAVIES, S</creatorcontrib><creatorcontrib>KLEIN, D. F</creatorcontrib><creatorcontrib>LIEBOWITZ, M. R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of clinical psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SIMPSON, H. B</au><au>SCHNEIER, F. R</au><au>CAMPEAS, R. B</au><au>MARSHALL, R. D</au><au>FALLON, B. A</au><au>DAVIES, S</au><au>KLEIN, D. F</au><au>LIEBOWITZ, M. R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Imipramine in the treatment of social phobia</atitle><jtitle>Journal of clinical psychopharmacology</jtitle><addtitle>J Clin Psychopharmacol</addtitle><date>1998-04-01</date><risdate>1998</risdate><volume>18</volume><issue>2</issue><spage>132</spage><epage>135</epage><pages>132-135</pages><issn>0271-0749</issn><eissn>1533-712X</eissn><coden>JCPYDR</coden><abstract>We report the results of an 8-week open trial of imipramine in 15 patients with social phobia. Nine patients completed the trial; six dropped out early because of adverse effects. The mean reduction in the Liebowitz Social Anxiety Scale was 15% and 18% for the intent-to-treat and completer groups, respectively; the overall response rate (based on the Clinical Global Impression Scale of 1 or 2, very much or much improved) was 20% (3/15) and 22% (2/9), respectively. The results from this open trial do not support the efficacy of imipramine as a treatment for social phobia.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>9555598</pmid><doi>10.1097/00004714-199804000-00005</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0271-0749 |
| ispartof | Journal of clinical psychopharmacology, 1998-04, Vol.18 (2), p.132-135 |
| issn | 0271-0749 1533-712X |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00004714_199804000_00005 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Antidepressive Agents, Tricyclic - adverse effects Antidepressive Agents, Tricyclic - therapeutic use Biological and medical sciences Female Humans Imipramine - adverse effects Imipramine - therapeutic use Male Medical sciences Middle Aged Neuropharmacology Pharmacology. Drug treatments Phobic Disorders - drug therapy Phobic Disorders - psychology Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Single-Blind Method |
| title | Imipramine in the treatment of social phobia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T13%3A49%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Imipramine%20in%20the%20treatment%20of%20social%20phobia&rft.jtitle=Journal%20of%20clinical%20psychopharmacology&rft.au=SIMPSON,%20H.%20B&rft.date=1998-04-01&rft.volume=18&rft.issue=2&rft.spage=132&rft.epage=135&rft.pages=132-135&rft.issn=0271-0749&rft.eissn=1533-712X&rft.coden=JCPYDR&rft_id=info:doi/10.1097/00004714-199804000-00005&rft_dat=%3Cpubmed_cross%3E9555598%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9555598&rfr_iscdi=true |